Q2 2022 · —
Revenue—
Net Income-$29.35M-$29.35M N/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$1.76-$1.76 no prior Q2 2021 on fileN/M vs Q1 2022
Operating Income-$26,305,000—
Operating Cash Flowderived-$20,223,000—
Free Cash Flowderived-$25,025,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2022 | Q2 2021 |
|---|---|---|
| Net Income | -$29.35M | $616.00K |
| EPS Diluted | -$1.76 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR